Hims & Hers Health (HIMS) is a strong buy due to its transformation into a profitable platform, a strategic partnership with Novo Nordisk, and aggressive global expansion, justifying a $29 price target.
Source Post
HIMS Surges 57% on Novo Deal – $29 Incoming! | HIMS Stock Analysis Podcast
Apr 15, 2026
Hims & Hers Health (HIMS) has undergone a significant transformation, evolving from a loss-making telehealth disruptor to a profitable, globally scaled platform. A recent watershed deal with Novo Nordisk, allowing HIMS to distribute branded Ozempic and Wegovy, has de-risked its obesity care segment and driven a 57% stock surge. Despite valuation concerns and past regulatory headwinds, the company's strong growth, profitability, and strategic international expansion via the Eucalyptus acquisition position it for long-term success, with a price target of $29.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
HIMSbuy opened Apr 15, 2026
+41.57%